Sponsored Links

Featured Links

Other Topics
Sponsored Links



Quote of the Day

"A baby is born with a need to be loved - and never outgrows it."

Frank A. Clark

FEATURED
HEALTH
PRODUCTS
 
Guide To Healthier Eating And Weight
 
The Ultimate Collection Of Health Ebooks
 
A Healthy Back In Ten Minutes A Day
 
Complete Guide To Healthy Eating
 
Natural Health Remedies To Help Stress
 




 


Google

 
Featured Diabetes Articles

A Strict schedule for Diabetes
The goal of every diabetic is to live a long and livable life. It is more important for the parents of small children with diabetes. As long as they manage their blood sugar, they can enjoy their life. It is not different for diabetics to display sudden ...

Diabetes and Your Heart
Diabetes is one condition that must be treated as soon as it is diagnosed, even though in its early stages it doesn't hurt, or cause inconvenience, or create any worrisome symptoms. But ignoring it is a mistake, because the blood sugar imbalance we ...

Weight Loss? Insulin Resistance May Be Your Problem
Can't Lose Weight? Syndrome X May Be the Culprit By ElmerFizz.com http://www.elmerfizz.com "I've put on 40 pounds in one year!" "It doesn't matter how much I workout, I can't lose weight." "My doctor must think I'm eating pizzas in the closet." ...





Control diabetes
 
Salacia oblonga: Proven anti diabetic and anti obesity Ayurvedic herb

To get this herb please visit www.salaciaoblongacapsules.com

Salacia oblonga (Celastaceae), "Ponkoranti", is a woody plant found in the forests of Sri Lanka and India. The roots and stems of Salacia Oblonga have been used extensively in Aryuveda and traditional Indian medicine for the treatment of Diabetes.

Recently, it has been found that a-Glucosidase inhibitors are potent therapeutic agents in carbohydrate-metabolic disorders such as Diabetes Mellitus.

Salacia Oblonga contains two potent a-Glucosidase inhibitors: Salicinol and Kotalanol 9. Methanol extracts from the roots of Salacia Oblonga exhibit an inhibitory effect on the increase of serum glucose levels in sucrose- and maltose-loaded rats. Salacia Oblonga has also been found to show inhibitory activity on Aldose Reductase which is related to such chronic diabetic complications as peripheral neuropathy, retinopathy, and cataracts.

Superior in terms of safety compared to chemically synthesized products, Salacia Oblonga is an effective anti-diabetic and dieting agent. Salacia Oblonga is more than 200 times stronger than Acarbose, an a-Glucosidase inhibitor manufactured by Bayer Corp.

In a study conducted by Kowsalya et at., it was determined that 2.5 to 5.0 grams of Salacia Oblonga daily is effective in lowering the blood glucose, serum cholesterol, triglycerides and increasing the HDL cholesterol levels of non-insulin dependent diabetes patients.

It is know that glucose absorbed in the body is converted into glycogens and neutral lipids by insulin and then accumulates as body fat and organ fat, thus causing obesity.

Salacia Oblonga inhibits the breakdown of oligosaccharides (disaccharides and trisaccharides) such as sucrose, maltose, etc. into monosaccharides and inhibits the absorption of monosaccharides such as glucose, mannose, etc. in the body, preventing blood sugar levels from rising.

The presence of S.oblonga extract tended to lower postprandial glycemia and significantly reduced the postprandial insulin response. The increase in breath hydrogen excretion suggests a mechanism similar to prescription alpha-glucosidase inhibitors.


About the Author
We are manufacturer of Salacia oblonga capsules

Diabetes News



New York Daily News

Heart Deaths in Diabetes Plummet
MedPage Today
The death rate from cardiovascular disease in US adults with diabetes fell 40% from 1997 to 2004, CDC and NIH researchers said. Data from the National Health Interview Survey (NHIS) and National Death Index over this period showed that, ...
Death rate drops among Americans with diabetes -CDCReuters
US Sees Drop in Deaths Linked to DiabetesU.S. News & World Report
Study: People are living longer with diabetesNew York Daily News
MarketWatch (press release) -Los Angeles Times
all 489 news articles »

Eli Lilly: Diabetes Drug Meets Cardiovascular Goals
Wall Street Journal
(LLY) said dulaglutide, an investigational treatment for Type 2 diabetes, met a primary endpoint for blood pressure and heart rate effects in a 16-week study. Dulaglutide, which is being studied as a once-weekly treatment for diabetes, was administered ...
Eli Lilly's diabetes drug meets mid-stage trial goalReuters
Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on ...PR Newswire (press release)
Eli Lilly Says Dulaglutide Meets Primary Endpoint - Quick FactsNASDAQ

all 24 news articles »

Diabetes Drug Target Identified
Science Daily (press release)
ScienceDaily (May 21, 2012) — New research from the University of Cincinnati (UC) points to the naturally produced protein apolipoprotein A-IV (apoA-IV) as a potential target for a new diabetes therapeutic. Patrick Tso, PhD, professor in the UC ...
Apofore Founder Publishes Studies Identifying Apolipoprotein A-IV as New ...MarketWatch (press release)

all 4 news articles »

Medgadget.com

Diabetes Design Demo Day Semi-Finalist: N4A Diabetes Care Center
Medgadget.com
by Nicholas Genes on May 22, 2012 • 2:26 pm Among all the semi-finalists for Sanofi's Data Design Diabetes Demo Day, we think N4A Diabetes Care Center was the most unexpected and confusing. N4A dates back to 1960′s legislation on aging, and is a loose ...
Beaufort man advances to semifinals in diabetes innovation challengeHilton Head Island Packet

all 6 news articles »

A Sweet Life

Novo Nordisk diabetes drug gets broader approval
CBS News
NEW YORK — Danish drugmaker Novo Nordisk A/S said Tuesday that the Food and Drug Administration granted an additional marketing approval for its diabetes drug Levemir. Novo Nordisk says Levemir is now approved for use in children with type 1 diabetes ...
FDA Approves Levemir® for Expanded Use in Children Two to Five Years of Age ...MarketWatch (press release)
Novo Nordisk Diabetes Drug Approved For ToddlersInvestor's Business Daily
Novo Nordisk's Levemir Insulin Approved for Use in Children as Young as TwoA Sweet Life
Drug Store News
all 13 news articles »